1 Ocak 2018 Dergi makalesi Açık Erişim

Yuksel, Melike; Biberoglu, Kevser; Onder, Seda; Akbulut, K. Gonca; Tacal, Ozden

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/37007</identifier>
  <creators>
    <creator>
      <creatorName>Yuksel, Melike</creatorName>
      <givenName>Melike</givenName>
      <familyName>Yuksel</familyName>
      <affiliation>Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Biberoglu, Kevser</creatorName>
      <givenName>Kevser</givenName>
      <familyName>Biberoglu</familyName>
      <affiliation>Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Onder, Seda</creatorName>
      <givenName>Seda</givenName>
      <familyName>Onder</familyName>
      <affiliation>Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Akbulut, K. Gonca</creatorName>
      <givenName>K. Gonca</givenName>
      <familyName>Akbulut</familyName>
      <affiliation>Gazi Univ, Sch Med, Dept Physiol, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Tacal, Ozden</creatorName>
      <givenName>Ozden</givenName>
      <familyName>Tacal</familyName>
      <affiliation>Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Toluidine Blue O Modifies Hippocampal Amyloid Pathology In A Transgenic Mouse Model Of Alzheimer'S Disease</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2018</publicationYear>
  <dates>
    <date dateType="Issued">2018-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/37007</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.biochi.2017.12.004</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Recently, we have demonstrated that toluidine blue O (TBO), a phenothiazine dye, shows inhibitory effects on both cholinesterases and amyloid pathology in Alzheimer's disease (AD) cellular model. In the present study, we aimed to determine the effects of TBO (in a purity of 85%) on amyloid and tau pathologies in a triple transgenic mouse model of AD (3xTg-AD). Beginning at 7.5 (mild pathology) or 13 (severe pathology) months of age, 3xTg-AD mice were treated intraperitoneally with 4mg/kg TBO or vehicle daily for 30 days. TBO treatment significantly reduced the levels of insoluble A beta 40 and A beta 42 in the hippocampi of mild and severe pathology groups compared to vehicle-treated counterparts. When the levels of full-length amyloid precursor protein (APP) and beta-site APP-cleaving enzyme 1 (BACE1) were assessed in 3xTg-AD mice at late pathological stage, no significant changes were observed after TBO treatment. Similarly, TBO did not recover hyperphosphorylation of tau at residues Thr181 and Ser202/Thr205 significantly in soluble and insoluble hippocampal fractions of 3xTg-AD mice. Taken together, the current study is the first in vivo report, to our knowledge, demonstrating that TBO mitigates amyloid pathology in 3xTg-AD mice with no apparent change on tau phosphorylation. Overall, the preliminary data presented here support the possible use of TBO as a disease-modifying drug for AD treatment. (C) 2017 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.</description>
  </descriptions>
</resource>